Gestational trophoblastic disease: What have we learned in the past decade? Journal Article


Author: Jones, W. B.
Article Title: Gestational trophoblastic disease: What have we learned in the past decade?
Abstract: Hydatidiform moles can be classified into two distinct entities: complete and partial. Complete moles are androgenetically derived, are characterized by a predominance of the 46,XX karyotype, and are associated with a significantly higher incidence of malignant sequelae than are partial moles. A subset of complete moles resulting from dispermy are heterozygous (46,XY) and appear to be associated with the greatest risk of malignancy. Free subunits of human chorionic gonadotropin, β core fragments, and acidic variants of human chorionic gonadotropin can now be readily measured by radioimmunoassays, fluoroimmunoassays, or isoelectric focusing techniques. Determination of these markers can be of value not only in monotoring response to therapy, but also as prognostic indicators. A subgroup of patients, traditionally classified as "high risk" or poor prognosis, who show poor responses to conventional combination chemotherapy have recently been designated as "ultra-high-risk" patients. They require more complex chemotherapy and possibly surgery and radiotherapy to achieve remission. The development of chemotherapy over the past decade, including the introduction of etoposide and cisplatin into current protocols and the treatment of patients with advanced gestational trophoblastic disease, are considered in this review. © 1990.
Keywords: cancer chemotherapy; cisplatin; combined modality therapy; chemotherapy; etoposide; antineoplastic combined chemotherapy protocols; tumor markers, biological; risk factors; cytogenetics; pregnancy; karyotyping; uterine neoplasms; choriocarcinoma; trophoblastic neoplasms; chorionic gonadotropin; hydatidiform mole; trophoblastic disease; prognosis; human; female; priority journal; article
Journal Title: American Journal of Obstetrics and Gynecology
Volume: 162
Issue: 5
ISSN: 0002-9378
Publisher: Elsevier Inc.  
Date Published: 1990-05-01
Start Page: 1286
End Page: 1295
Language: English
DOI: 10.1016/0002-9378(90)90039-a
PUBMED: 2160194
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Walter   Jones
    95 Jones